Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  Fagron    FAGR   BE0003874915

FAGRON

(FAGR)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
03/13/2019 03/14/2019 03/15/2019 03/18/2019 03/19/2019 Date
16.16(c) 16.07(c) 16.11(c) 15.96(c) 16.01 Last
94 657 97 653 160 579 66 656 6 600 Volume
-1.34% -0.56% +0.25% -0.93% +0.31% Change
More quotes
Financials (EUR)
Sales 2019 523 M
EBIT 2019 93,3 M
Net income 2019 63,3 M
Debt 2019 197 M
Yield 2019 0,88%
Sales 2020 575 M
EBIT 2020 109 M
Net income 2020 75,8 M
Debt 2020 135 M
Yield 2020 1,07%
P/E ratio 2019 18,45
P/E ratio 2020 15,32
EV / Sales2019 2,57x
EV / Sales2020 2,23x
Capitalization 1 147 M
More Financials
Company
Fagron specializes in the development, marketing and distribution of healthcare products and services intended for healthcare professionals and institutions. The group ensures the sale of pharmaceutical formulas and raw materials, provides third-party pharmaceutical compounding services to... 
Sector
Pharmaceuticals
Calendar
04/12 | 02:00amSales and Revenue Release
More about the company
Surperformance© ratings of Fagron
Trading Rating : Investor Rating :
More Ratings
Latest news on FAGRON
02/08FAGRON : launches new brand identity and purpose
AQ
02/07FAGRON : realized turnover growth of 14.5%; REBITDA increased to € 99.1 million
GL
2018NUVO PHARMA : Pharmaceuticals Announces 2018 Third Quarter Results
AQ
2018FAGRON NV : Disclosure of received notification
GL
2018FAGRON : continues strong turnover growth of first semester in the third quarter..
AQ
2018FAGRON : continues strong turnover growth of first semester in the third quarter..
GL
2018FAGRON : 3rd quarter earnings
CO
2018FAGRON NV : quaterly sales release
2018FAGRON NV : - Disclosure of received notification
AQ
2018FAGRON NV : Disclosure of received notification
AQ
More news
Analyst Recommendations on FAGRON
More recommendations
Sector news : Pharmaceuticals - NEC
03/18EXCLUSIVE : Sanofi says working on CEO succession plan
RE
03/18SANOFI : Working on CEO Succession Plan -Reuters
DJ
03/18GLOBAL MARKETS LIVE : ING, Boeing, GM, Worldpay…
03/18ASTRAZENECA : Farxiga Trial Shows Reduction of Heart Problems in 16% of Patients
DJ
03/18ASTRAZENECA : Gets Orphan Drug Designation for Lung Disease Treatment
DJ
More sector news : Pharmaceuticals - NEC
Chart FAGRON
Duration : Period :
Fagron Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FAGRON
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 19,1 €
Spread / Average Target 20%
Managers
NameTitle
Rafael Padilla Papaceit Chief Executive Officer & Director
Koen Hoffman Chairman
Karin de Jong Chief Financial Officer & Executive Director
Giulia van Waeyenberge Independent Director
Frank Jozef Paul Vlayen Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
FAGRON11.76%1 301
JOHNSON & JOHNSON6.63%366 397
NOVARTIS11.61%238 367
ROCHE HOLDING LTD.11.61%233 055
PFIZER-4.28%231 954
MERCK AND COMPANY6.75%210 550